Increased albuminuria in bardoxolone methyl –treated type 2 diabetes patients: mere reflection of eGFR improvement?

Bardoxolone methyl activates nuclear factor erythroid 2-related factor 2 and increases glomerular filtration rate in patients with diabetic kidney disease. Because bardoxolone methyl also increases albuminuria, Rossing and colleagues performed a retrospective analysis of the Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON) study and attributed increased albuminuria to increased estimated glomerular filtration rate. Although the study emphasizes bardoxolone methyl ’s benefits in diabetic kidney disease, we must be careful about interpretation.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Commentary Source Type: research